Shockwave Medical, Inc. (36M.F)
- Previous Close
305.50 - Open
305.50 - Bid 306.60 x --
- Ask 309.80 x --
- Day's Range
305.50 - 305.70 - 52 Week Range
145.45 - 307.60 - Volume
5 - Avg. Volume
7 - Market Cap (intraday)
11.538B - Beta (5Y Monthly) 0.88
- PE Ratio (TTM)
85.39 - EPS (TTM)
3.58 - Earnings Date May 6, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
210.67
Shockwave Medical, Inc., a medical device company, develops and commercializes intravascular lithotripsy (IVL) technology for the treatment of calcified plaque in patients with peripheral and coronary vascular, and heart valve diseases in the United States and internationally. The company offers products for the treatment of peripheral artery disease (PAD), including M5 IVL catheter and M5+ IVL catheter, which are five-emitter catheters used in IVL system in medium-diameter vessels; S4 IVL catheter, a four-emitter catheter for use in IVL system in small-diameter vessels; and L6 IVL catheter, a six-emitter catheter used for IVL System in large diameter vessels. It also provides product for the treatment of coronary artery disease, such as C2 IVL catheter and C2+IVL catheter that are two-emitter catheters for use in IVL system; and Reducer, a device to treat refractory angina. In addition, the company develops COSIRA-II trial; shockwave C2 Aero, a coronary IVL catheter; shockwave javelin coronary, a non-balloon-based catheter platform to treat of tight, difficult-to-cross coronary lesions; shockwave L6; shockwave E8 catheter, to target long peripheral artery lesions; shockwave javelin peripheral, a non-balloon-based catheter platform, to treat tight, difficult-to-cross peripheral lesions. Further, it offers shockwave carotid IVL, a purpose-built IVL System to treat calcified carotid artery lesions; and Shockwave Crescendo, a platform developed to treat calcified, stenotic heart valves. It serves interventional cardiologists, vascular surgeons, and interventional radiologists through sales representatives and managers, and distributors. The company was incorporated in 2009 and is headquartered in Santa Clara, California.
shockwavemedical.comRecent News: 36M.F
Performance Overview: 36M.F
Trailing total returns as of 4/26/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: 36M.F
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: 36M.F
Valuation Measures
Market Cap
11.54B
Enterprise Value
11.33B
Trailing P/E
85.18
Forward P/E
68.49
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
17.16
Price/Book (mrq)
18.40
Enterprise Value/Revenue
15.52
Enterprise Value/EBITDA
59.17
Financial Highlights
Profitability and Income Statement
Profit Margin
20.17%
Return on Assets (ttm)
9.38%
Return on Equity (ttm)
24.96%
Revenue (ttm)
730.23M
Net Income Avi to Common (ttm)
147.28M
Diluted EPS (ttm)
3.58
Balance Sheet and Cash Flow
Total Cash (mrq)
990.55M
Total Debt/Equity (mrq)
115.24%
Levered Free Cash Flow (ttm)
112.47M
Research Analysis: 36M.F
Company Insights: 36M.F
36M.F does not have Company Insights